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Treatment for drug-resistant tuberculosis (DR-TB) is longer and associated with more significant 
side-effects than drug susceptible TB. Second line injectable therapy using kanamycin, amikacin 
or capreomycin is associated with irreversible hearing loss. There is a scarcity of literature 
regarding the frequency of hearing loss as well as associated risk factors, particularly with long 
term use. This study aimed to determine the incidence and risk factors for hearing loss among 
patients receiving second line injectable drugs. 
Method 
This was a retrospective cohort study that was conducted with patients from 11 primary health
care clinics in Khayelitsha, Cape Town. All adult patients aged 18 years and above with a
diagnosis of MDR-TB, XDR-TB or any other form of DR-TB receiving intramuscular amikacin
or kanamycin or capreomycin as part of the DR-TB regimen were included. Subjects needed to
have initiated DR-TB treatment between June 1, 2009 and Dec 31, 2010. Hearing was assessed
at baseline and then monthly for a minimum period of 6 months. Hearing was measured
objectively in a sound proof booth by an audiologist trained field worker using a pure tone
audiometer (Interacoustics AS608) and recorded on a standardized audiometry form. Hearing
was tested at the following frequencies: 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz and 8000Hz.
The exposure variables in this study included: age at DR-TB diagnosis, sex, starting
aminoglycoside dose, previous aminoglycoside use, HIV status, CD4 count and NRTI use. The
outcome variable in this study was hearing loss. Hearing loss was defined as a hearing threshold
of >20 decibels at any test frequency in at least both ears. Hearing was measured by averaging
the hearing thresholds at each visit for each ear separately from 250 Hz to 2000Hz for low
frequency loss and from 4000 Hz to 8000 Hz for high frequency loss. Logistic regression was













From June 1, 2009 to December 2010, 238 subjects meeting eligibility criteria started DR-TB 
treatment. Of these, 131 patients had at least one valid audiogram within 6 weeks of treatment 
initiation, and 47 (35.9%) patients had baseline hearing loss.  In multivariable analysis, older age 
and HIV infection with CD4<100 cells/µl increased odds of baseline hearing loss.  One hundred 
and nine patients had a second audiogram to assess deterioration.  Of these, 37 (33.9%) patients 
had deterioration in hearing that was primarily mild but 9 patients (8.3%) had severe bilateral 
hearing loss. In multivariable analysis, older age and baseline hearing loss predicted deterioration 
of hearing. 
Conclusion 
Hearing loss at baseline and during treatment occurred frequently and was often severe.
Increasing age and HIV infection with low CD4 count were associated with baseline hearing
loss. Baseline hearing loss and older age predicted deterioration of hearing.
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Title: Baseline prevalence and incidence and risk factors for  new-onset drug 
induced hearing loss in  adults receiving  drug resistant tuberculosis (DR-TB) 
treatment in Khayelitsha, South Africa. 
1. Introduction 
1.1 Background  
South Africa has a high burden of tuberculosis, and according to the 2012 World Health 
Organization (WHO) TB Global Report, it was ranked third among the 22 high burden countries, 
with a reported incidence of between 0.40 and 0.59 million cases in 2011.
1
 It also has a high 
burden of multidrug-resistant tuberculosis (MDR-TB), and data from the WHO, ranked South 




MDR-TB and XDR-TB pose a threat to effective TB control due to the difficulties in diagnosis, 
the requirement for prolonged chemotherapy for up to two years, increased cost (up to 100 times 
costlier than drug susceptible TB) and the use of more toxic second line drugs that are associated 
with increased adverse effects.
2 
Reported studies have shown that at least 60% of patients on MDR-TB therapy will experience 
adverse events. 
3,4 
The most serious s de effects are nephrotoxicity and ototoxicity which are 
caused by injectable second line agents such as amikacin, kanamycin and capreomycin,
5
 that are 
administered intramuscularly for a minimum period of 6 months as per the National Tuberculosis 
guidelines.
6
 Nephrotoxicity is reversible with discontinuation of therapy whilst ototoxicity is not. 
Ototoxicity comprises of damage to hearing and/or balance.  This study will focus on the hearing 
loss component of ototoxicity. 
The prevalence of hearing loss amongst DR-TB patients ranges from as low as 6% 
7
 up to 
50%.
3,8,9,10,11   
Variation  in hearing loss data may be due to factors such as different patient 
demographics, dose of injectable, duration of injectable use, type of injectable used , method of 















Risk factors that are known to predict hearing loss include; older age, duration of injectable 
therapy, total cumulative dose,
13
 size of aminoglycoside dose, history of aminoglycoside use,
noise exposure, presence of mitochondrial DNA mutations,
9
 HIV co-infection, opportunistic
infections and use of nucleoside reverse transcriptase inhibitors (NRTIs).
14
  Despite this
evidence, inconsistencies of data pertaining to risk factors for hearing loss remain. 
Anecdotally, the prevalence of hearing loss due to second line injectable use in Khayelitsha is
quite high and is therefore cause for concern. There is a scarcity of literature on aminoglycoside
induced hearing loss, in particular, risk factors associated with this adverse effect in long term
DR-TB studies.
12
Most of the literature on hearing loss is based on short term aminoglycoside
use with limited studies assessing hearing loss during long term TB therapy. Furthermore, most
of the studies have been conducted in developed countries where patient profiles would be
expected to be different to those in a developing country. Hence, generalizability to the South
Africa context may be a challenge. It is against this dearth of literature on hearing loss that this
study will be conducted.
1.3 Aims/objectives of the research 
The overall aim of this study is to determine the baseline prevalence of initial hearing loss and
incidence of hearing deterioration during treatment as well as the risk factors associated with
aminoglycoside/capreomycin induced hearing loss in adult patients with DR-TB.  
Other secondary objectives of the study include:
• To measure the  type and severity of hearing loss at start of treatment (baseline hearing
loss)
• To measure the type and severity of  deteriorating hearing loss during DR-TB treatment
• To determine overall prevalence of worsening hearing amongst those with baseline
hearing loss
• To determine risk factors associated with  baseline hearing loss and deterioration of











This study will focus on the following measurable risk factors: age at DR-TB diagnosis, sex, 
starting aminoglycoside dose, prior aminoglycoside use, HIV status, CD4 count, anti-retroviral 
therapy use, in particular use of nucleoside reverse transcriptase inhibitors (NRTIs).  Injectable 
duration and total aminoglycoside dose will be collected but not included in the final analysis as 
the current dataset does not allow for us to determine the timing of hearing loss. This is because 
most patients had irregular audiograms with only a few individuals having at least 6 audiograms; 
thereby limiting our ability to determine timing of hearing loss with the current dataset.  
2. Method
2.1 Study design and study setting 
This is a retrospective cohort study that will be conducted with patients attending 11 primary
health care clinics in Khayelitsha, Cape Town. This is a peri-urban sub-district within the Cape
Metro area that has one of the highest TB incidence rates in the country with 60% to 70% of TB
patients also co-infected with HIV. 
15
The Khayelitsha decentralized DR-TB programme was
established in 2007 in response to the high DR-TB burden and lack of capacity of the local TB
hospital to handle all cases resulting in treatment delays.
15
Hence all DR-TB cases that do not
have severe disease requiring hospitalization receive outpatient care and are followed up closely
by treatment counselors. 
2.2 Study Participants 
All adult patients aged 18 years and above with a diagnosis of MDR-TB, XDR-TB or any other
form of DR-TB who are receiving intramuscular amikacin, kanamycin or capreomycin as part of
the DR-TB regimen will be included into the study. Subjects need to have initiated DR-TB
treatment between June 1, 2009 and Dec 31, 2010. Our cohort period will begin in June 2009 and
not earlier because audiometry testing only became standard of care in Khayelitsha from 2009.  
2.3 Study Procedures 
There will no formal recruitment process for study participants as collection of audiometry data 












At baseline, all patients who meet the inclusion criteria will be entered into the study. Upon 
treatment initiation, all demographic and clinical information is collected in a standardized form 
by the attending physician as part of standard of care (See Appendix 1 for standardized form). 
Thereafter, the patient will receive a referral to the audiometry testing centre based at Ubuntu 
Clinic (one of the 11 Khayelitsha primary health care clinics). 
Hearing is measured objectively by an audiologist trained field worker using a pure tone
audiometer (Interacoustics AS608) and recorded on a standardized audiometery form (See
Appendix 2 for copy of audiometry form). This will be conducted in a sound proof booth at the
following frequencies: 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz and 8000Hz. Prior to doing the
hearing assesment, the ear canal will be examined using an otoscope for any signs of obstruction
such as inflammation, growths, foreign bodies or excessive cerumen because obstructions impair
the transmission of sound.
16
The picture below is an illustration of the sound proof booth that is used to perform audiometry
testing at Ubuntu Clinic in Khayelitsha.
The reliability of the audiometry measurements will be assessed using test retest reliability at 











Hence, a valid audiogram will be defined as one that does not have any ear(s) obstructed and one 
that is classified as having good reliability.   
Follow-up Visit 
Patients in Khayelitsha are routinely followed up on a monthly basis until 2 months after the end 
of the injectable phase, typically a 6 to 8 month period. During the follow-up visits, 
ascertainment of hearing loss is measured quantitatively using audiometry.  All audiometry data 
collected at follow-up visits is compared with baseline data (if available) to determine whether 
deterioration of hearing has occurred (See appendix 2 for copy of audiometry form). 
2.4 Exposure and outcome variables 
The exposure variables in this study include: age at DR-TB diagnosis, sex, starting
aminoglycoside dose, previous history of aminoglycoside use, HIV status, CD4 count and NRTI
use.  
The outcome variable in this study is hearing loss. Hearing loss will be defined as a hearing
threshold of >20 decibels at any test frequency in at least both ears. 
Hearing loss will be categorized into three frequencies: i) low frequency hearing loss (250 Hz to
2000Hz ) ; ii) high frequency hearing loss (4000Hz and 8000 Hz) and; iii) mixed hearing loss-
hearing loss occurring in both low and high frequencies. 
For low frequency hearing loss, hearing sensitivity will be measured by averaging the hearing
thresholds across 250 Hz, 500Hz, 1000Hz and 2000Hz for each ear separately at each visit. For
high frequency hearing loss, hearing sensitivity will be measured by averaging hearing
thresholds across 4000 Hz and 8000 Hz for each ear separately at each visit. This method has
been shown to be effective in assessing changes in hearing loss. 
17
The criteria for determining the presence of hearing loss and assessment of severity of hearing 
loss as defined by Gelfand (2009) will be used.
18
 However, we will modify the criteria slightly in
order to have fewer categories.  The criteria used will be as follows: i) Normal hearing: Hearing 
threshold of ≤ 20 decibels at either the low or high frequency test frequencies; ii) Mild hearing 











iii) Moderate to severe hearing loss: Hearing threshold of between 41 and 70 decibels at either
low or high test frequencies and iv) Severe to profound hearing loss: Hearing threshold of more 
than 70 decibels across the low or high frequencies. Hearing loss severity will be assessed using 
the WHO better ear criteria for grading hearing impairment.
19
 This stipulates that severity is
categorized according to the ear with less severe hearing loss. 
2.5 Assessment of hearing loss 
Hearing severity will be measured semi-qualitatively. This will consist of plotting each patient’s
audiogram using calculated averages of hearing thresholds across low and high frequencies for
each ear separately. This will be restricted to valid audiograms only. Hence, each subject will
have four line graphs, for low and high frequency and for each ear separately. The line graphs
will be assessed qualitatively by two independent assessors to determine whether hearing loss is
present at baseline and whether deterioration has occurred with treatment. All discrepancies will
be resolved by consensus. A qualitative assessment (without the use of statistical software) will
be used because of the variation seen in audiometry readings making it difficult to do a
quantitative assessment (See appendix 3 for examples of audiometry line graphs).
Audiograms for assessment of deterioration of hearing
The first ever audiogram for each patient will be classified relative to the start of TB treatment:
i) Pre-treatment audiograms will be defined as audiograms taken within 10 days of initiating
DR-TB treatment, prior to significant drug exposure ii) Early treatment audiograms will be
defined as audiograms taken within 1.5 months of starting DR-TB treatment. Only patients with
a pre-treatment audiogram or an early treatment audiogram will have deterioration of hearing
measured. Hearing loss that occurs within 1.5 months of treatment start will be referred to as
baseline hearing loss.  
2.6 Other data sources
Electronic databases will be used to collect data on the following variables: i)  Demographic 
variables- age, sex and weight; ii) Clinical variables- HIV status, CD4 count, type of DR-TB, 
previous TB history; iii) Treatment variables- type of aminoglycoside, starting injectable dose 











3 Statistical Analysis 
The baseline characteristics of the cohort will be described using medians and inter quartile 
ranges for variables with a skew distribution and means and standard deviations for the normally 
distributed data. Wilcoxon rank-sum test and t tests will be used to measure differences between 
numerical variables where appropriate.  The categorical variables will be analyzed using Fishers 
Exact Test and Chi-squared test where appropriate. Percentages will be used to describe the 
frequency, type and severity of hearing loss at start and during treatment. 
Bivariate associations between hearing loss and explanatory variables will be assessed using
logistic regression. Explanatory variables for inclusion into the model will be based on apriori
assumptions derived from previous studies. Multivariable logistic models will used to test the
association between hearing loss and the explanatory variables. All statistical analysis will be
conducted using STATA version 11 (StataCorp, College Station, Texas).
4 Ethics 
4.1 Privacy and Confidentiality 
The patient’s identity will be kept confidential by de-identifying the patient using unique patient
identification numbers when data is transferred to the electronic database. The database will be
password protected and only the investigators in the study will have access to this information.
All information in hard copy will be stored in a locked cupboard in the Médecins Sans Frontières
office in Khayelitsha. 
4.2 Potential Risks and benefits 
The potential risks in this study are minimal since it is an observational study and all procedures 
and data collection are part of standard of care. However, the results of the audiometry testing 
classify a person as having hearing loss and this may be considered a potential risk to the patient 
with regards to factors such as job security or social life. The patients are routinely referred for 
further management at Tygerberg Hospital if they experience moderate severe or severe 













In terms of benefiting the wider community, the results of the research will enable health care 
providers to better understand the risk factors that are associated with hearing loss. This will 
enable them to implement early interventions in high risk patients e.g. more frequent monitoring, 
lower injectable dosage, or shorter duration of injectable therapy. 
4.3 Feedback and dissemination of results 
The results of this study will be disseminated to all staff members at Médecins Sans Frontières 
and medical personnel at the Khayelitsha clinics and Cape Town City Health.  Wider 
dissemination to the scientific community will be in the form of a peer reviewed scientific paper. 
4.4 Reimbursement for Participation and patient informed consent 
There will be no reimbursement of participants because all procedures that will be carried out are 
all part of standard of care.  
4.5 Patient Informed consent 
This is not applicable in this study since the patient is receiving standard of care. 
4.6 Ethical approval 
Ethical approval will be sought from the University of Cape Town and Cape Town City Health 
(Appendix 4- Copy of ethical approval from University of Cape Town and City Health). 
4.6 Budget 
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Title: Baseline prevalence and incidence and risk factors for new-onset 
drug induced hearing loss in adults receiving drug resistant tuberculosis 
(DR-TB) treatment in Khayelitsha, South Africa. 
1. Aims/objectives of the literature review
The overall aim of this literature review is to describe the frequency and risk factors of 
aminoglycoside/capreomycin induced hearing loss in adult patients with drug resistant 
tuberculosis (DR-TB). 
Other secondary aims or objectives of the literature review include: 
• To briefly describe the prevalence of pulmonary tuberculosis (TB) and DR-TB in
South Africa
• To describe the mechanism of hearing loss caused by aminoglycosides or
capreomycin
• To briefly describe the pharmacokinetics of aminoglycosides and capreomycin
• To describe the incidence /prevalence of aminoglycoside/capreomycin induced
hearing loss in adults
• To  describe the type of hearing loss
2. Search strategy
The literature search included all English language articles published until December
2012. Studies were primarily identified using key word searches of electronic databases
such as Pubmed, Ebsco Host, Science Direct and Google Scholar. A few studies were
identified from reference lists of published articles. The key words used to identify
articles included: hearing loss, hearing impairment, ototoxicity, aminoglycosides, drug
resistant tuberculosis, HIV/AIDS. Studies were included if they comprised of adult
patients receiving aminoglycosides or capreomycin for short term use (5-7 days) or long
term use (>1 month). There was no restriction on study design.
3. Background
South Africa is one of the highest tuberculosis (TB) burden countries in sub-Saharan 
Africa. According to the 2012 World Health Organization (WHO) Global TB report, 











incident TB cases of between 0.4 million and 0.5 million and corresponding incident rate 
of 993 per 100,000.
1
 South Africa also has a high burden of drug resistant tuberculosis 
(DR-TB). There has been an upward trend in the number of laboratory confirmed DR-TB 
cases in South Africa since 2006, possibly due to increased case detection and growth in 
the HIV epidemic.
2
 In 2006, there were 464 laboratory confirmed MDR-TB cases
2
 
compared to 10,085 MDR-TB cases in 2011.
1 
The 2011 estimates represented the second 
highest case notification amongst the 27 high burden MDR-TB countries.
1
 There is also a 
high burden of extensively drug-resistant tuberculosis (XDR-TB) with a total of 573 




DR-TB poses a threat to effective TB control due to the difficulties in diagnosis, the 
requirement for prolonged chemotherapy for up to two years, increased cost ( up to 100 
times higher) and the use of more toxic second line drugs that may be associated with 
increased adverse effects.
3 
In addition, there are delays with DR-TB diagnosis, 
particularly in places where GeneXpert has not been rolled out and culture is still being 
used to detect DR-TB. Another problem with diagnosis of DR-TB in South Africa is that 
drug susceptibility testing is only done in patients who have failed first line treatment, 
and by time a diagnosis has been made, some patients may have already died.    
 
Studies have shown that at least 60% of patients on MDR-TB chemotherapy will 
experience an adverse effect. 
4,5,6
 Nephrotoxicity and ototoxicity are the two major dose-
related adverse effects associated with aminoglycosides and capreomycin.
7
 
Nephrotoxicity is reversible upon discontinuation of drug therapy whilst ototoxicity is 
irreversible and is defined as damage to hearing and/or balance functions of the ear.
7 
This 
literature review will be focusing primarily on the hearing loss component. The 2011 
National South African guidelines for DR-TB that are based on the WHO guidelines  
recommend  amikacin / kanamycin as the aminoglycosides of choice for the treatment of 
















3.0 Pharmacokinetics and therapeutic dose of aminoglycosides and capreomycin 
Amikacin and kanamycin are completely absorbed from IM injection sites and well 
distributed in extracellular fluids and body tissues. 
9
 Capreomycin is also poorly absorbed
orally and is administered intramuscularly. Excretion of these drugs is primarily through 
the renal route (70 to 95%) of dose, and accumulation occurs in renal impairment. 
9
 The
adult therapeutic dose of amikacin/kanamycin in DR-TB treatment is 15mg/kg to a 
maximum of 1g daily. 
9
 The capreomycin dose is 750-1000mg/day to a maximum of
20mg/kg/day. 
9
 Ototoxicity is a dose related side effect and will occur at the higher end of
therapeutic doses or if the therapeutic doses are exceeded. 
3.1 Mechanism of ototoxicity 
Amikacin, kanamycin and capreomycin are chiefly cochleatoxic.
10
 The ototoxicity of
aminoglycosides occurs mainly through the loss of cochlear or vestibular sensory cells
(hair cells) or both. 
11
The irreversible destruction of sensory cells in the cochlea leads to
permanent hearing and begins with the outer hair cells at the base of the cochlea
(responsible for high frequency sound) and then spreads to the apex (responsible for low
frequency sound). 
11
Hence; high frequency hearing loss generally occurs before low
frequency hearing loss. Initially, it was thought that ototoxicity occurred through
accumulation of aminoglycosides in the peri-lymph in the inner ear. It is now clear that
aminoglycosides do not cause hearing loss through this mechanism, since
pharmacokinetic studies have shown that the inner ear concentrations do not exceed
plasma concentrations. 
11, 12  
Cumulative evidence has now established that reactive 
oxygen species (free radicals) are the mechanism behind aminoglycoside hearing 
impairment. 
11,12
 It is postulated that aminoglycosides cause an imbalance in the inner ear
through excessive formation of free radicals which triggers cell death pathways leading to 
cell apoptosis/ necrosis of sensory cells in the cochlea, which leads to permanent hearing 
impairment. 
11
4. Incidence and type of hearing loss
The literature on the reported incidence of adult hearing loss due to aminoglycosides or 











from a few percent to 33%, 
12
 whilst in another systematic review of 35 studies, hearing
loss was reported to be as low as 10% in some studies, and approaching or exceeding 
50% in other studies. 
13
  Yet another systematic review of 15 studies, reported a hearing
loss incidence ranging from 0% to 55%.
14
  In short term use (5-7 days) of
aminoglycosides, the reported incidence of hearing loss is as high as 22%.
15
The variation in hearing loss observed across studies is due to factors such as sensitivity 
of the testing methodology, study methodology, patient demographics, previous TB 
treatment, drugs used, dosages used, duration of aminoglycoside treatment or co-morbid 
diseases. 
13
Despite the variation in hearing loss incidence in the literature, there is consistency
regarding the frequency range (Hz) at which hearing loss presents initially, with data
from a systematic review of DR-TB patients reporting high frequency hearing loss
occurring more frequently.
14
5. Risk factors of hearing loss
The first aminoglycoside to be developed in the 1940’s was streptomycin and it was
isolated from Streptomyces griseus by Waksman and co-workers. 
12
Subsequently, other
aminoglycosides such as amikacin and kanamycin as well as capreomycin were
developed. The ototoxicity profile of aminoglycosides has been well described in earlier
studies describing short term use of these drugs for bacterial infections, but studies on
long term use such as DR-TB are lacking. The risk factors that have been associated with
hearing loss include older age, duration of aminoglycoside/capreomycin therapy, dose, 
prior exposure to aminoglycosides, noise exposure, specific mitochondrial mutations, 
7
HIV positive status, opportunistic infections and use of ototoxic medicines.
16
 This
literature review will focus on the following risk factors: age, duration of aminoglycoside
therapy, aminoglycoside dose, previous aminoglycoside use, genetic susceptibility, noise
exposure, previous TB disease, HIV status and opportunistic infections and use of











Table of studies of risk factors (age, duration of injectable and aminoglycoside dose) 
Year Author Title and journal 
1983 Moore eta l Risk factors for the development of auditory  toxicity in patients receiving 
aminoglycosides. J Infect Dis.  1984; 149 (1): 23-30. 
1987 Gatell et al Univariate and multivariate analyses of risk factors predisposing to auditory 
toxicity in patients receiving aminoglycosides. Antimicrob Agents Chemother. 
1987; 31(9): 1383-1387. 
2004 Peloquin  et al Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment 
of Mycobacterial Diseases. Clin Infect Dis. 2004; 38: 1538-1544. 
2002 De Jager et al Hearing Loss and nephrotoxicity in long-term aminoglycoside treatment in 
patients with tuberculosis. Int J Tuberc Lung Dis. 2002; 6(7): 622-627. 
2012 De Vasconcelos Audiometric evaluation of patients treated for pulmonary tuberculosis. J Bras 
Pneumol. 2012; 38(1): 81-87. 
2011 Sturdy et al Multidrug- resistant tuberculosis (MDR-TB) treatment in the UK: a study of
injectable use and toxicity in practice. J Antimicrob Chemother. 2011; 66
(8):1815-1820.
5.1 Age, duration of injectable therapy and aminoglycoside dose
Older age is considered a risk factor for hearing loss as it is associated with a decrease in
hair cells in the cochlea or a reduction in endogenous protective mechanisms such as
antioxidants; thereby exposure to ototoxic drugs increases ones susceptibility to this
adverse event. 
12
In addition, prolonged exposure to aminoglycosides (duration of therapy)
and higher cumulative doses have a direct additive effect on the damage of hair cells of
the cochlea, consequently leading to irreversible hearing loss. 
12
Despite these biological mechanisms explaining the effects of these variables on hearing
loss, studies on both short term and long term use of aminoglycosides have reported
conflicting data regarding age, duration of therapy and aminoglycoside dose . 
Moore et al. 
15 
determined the risk factors for auditory toxicity (hearing loss) using data
from three randomized, double-blind trials in patients receiving either intravenous 
2mg/kg of gentamicin/tobramycin or 8mg/kg of amikacin for bacterial infection. One 
hundred and thirty five patients were included if they had received at least nine doses of 
drug therapy.Hearing loss was defined as a decrease in consecutive audiograms of at least 
15 decibels (dB) in auditory acuity at any frequency in the range of 1000-8000 Hz. 
15
 The











aminoglycoside dose and duration of aminoglycoside therapy (P<0.05) but age did not 




The findings by Moore et al conflict with another study of short term use of 
aminoglycosides.  Gatell et al. 
17
 randomized 187 patients to intravenous tobramycin or 
netilmycin 1.7mg/kg 8 hourly or amikacin 7.5 mg/kg 12 hourly for bacterial infection. 
Hearing loss was defined as a decrease in auditory threshold of at least 15 dB in at least 
two frequencies in the range of 250 to 8000Hz unilaterally or bilaterally.  In the 
multivariate analysis, only increasing age was found to be significantly associated with 
auditory toxicity (P<0.00001). 
17
 Conversely the factors not significantly associated with 
auditory toxicity included duration of therapy and total aminoglycoside dose. 
17 
The 
contrasting results observed in these two studies may be attributed to the different 
definitions of hearing loss used, type of aminoglycosides used and older patient 
population in the Gatell et al study.  Furthermore, the duration of aminoglycoside therapy 
may also explain the differences. The duration of aminoglycoside therapy in patients with 
auditory toxicity was 7.9 and 9.1 days in the Gatell et al and Moore et al studies 
respectively. 
 
A more recent study of aminoglycoside induced hearing loss in treatment of 
mycobacterial disease including MDR-TB had some findings consistent with the 
aforementioned studies. Peloquin et al. 
18
 conducted a randomized trial of 87 adult 
patients based in US hospitals who received 25mg/kg three times weekly or 15mg/kg 
once daily of intravenous amikacin, streptomycin or kanamycin. Ototoxicity (hearing loss) 
was defined as ≥ 20dB neurosensory hearing loss from baseline in either ear at any 
frequency from 250 to 8000Hz. 
18
  Hearing loss occurred in 37% of the cohort and was 
significantly associated with increasing age, longer duration of aminoglycoside treatment, 
and greater total aminoglycoside dose received but not size of dose in mg/kg, dosing 
frequency or nephrotoxicity. 
18  
 
In contrast to the study by Peloquin et al 
18
, a retrospective study from the Netherlands 











De Jager et al. 
19
 included 110 adults with a diagnosis of DR-TB and other mycobacteria
infections who had received at least 14 days supply of kanamycin, amikacin or 
streptomycin.  Hearing loss was defined as loss of 15 dB at two or more frequencies, or a 
minimum of 20 dB hearing loss of at least one frequency between 250 and 8000Hz. 
19
Older age, total duration of aminoglycoside treatment, total aminoglycoside dose and 
renal function were not associated with hearing loss.  These contradicting results may be 
explained in part by the study design and the study population. This was a retrospective 
study and one of the limitations was the lack of baseline audiograms and variability in 
frequency of audiograms obtained, potentially underestimating the extent of hearing loss 
in this cohort. Furthermore, the study population was much younger with a mean age of 
35.7 years compared to a median age of 49 years in the study by Peloquin et al.  
Nonetheless, more recent retrospective studies of MDR-TB patients from Brazil and UK
have consistently shown a relationship between demographic factors and hearing loss, in
particular increasing age. 
20,21
 The study from Brazil showed that increasing age almost
trebled the odds of aminoglycoside induced hearing loss, (OR 2.8; 95%CI: 1.15-7.35). 
20
The UK study also examined the relationship between injection duration and total
aminoglycoside dose and hearing loss, but these variables failed to predict hearing loss. 
21
This may be explained by the premature discontinuation of aminoglycosides and
adjustment of doses reported in a sub set of patients experiencing auditory toxicity.
From the reported literature, increasing age appears to be a more consistent risk factor for
hearing loss in both short term and long term aminoglycoside use whilst injection
duration and total aminoglycoside dose have mixed results and are less predictive.  
However, the comparison of the above studies is limited by the dearth of data on long
term use of aminoglycosides in DR-TB, thereby necessitating the comparison of DR-TB
studies with studies reporting on short term aminoglycoside use.
5.2 HIV infection 
Hearing loss linked to HIV is classified as either, iatrogenic or non-iatrogenic. Non-











primary cause and opportunistic infections. 
22
 On the other hand, iatrogenic causes are 
more specific and relate to effects of any ototoxic drugs such as nucleoside reverse 




Hearing changes have been identified as one of the presentations at any stage of HIV 
disease. 
16
 However, there is a strong positive correlation between worsening hearing loss 
and progression of HIV disease.
 
This suggests that the higher the viral load, the higher the 
frequency of HIV associated hearing loss.  The exact mechanism of hearing loss due to 
HIV infection is unclear, but the HIV virus is considered to be a direct cause of hearing 
loss since it is neurotropic. 
16
 There is heterogeneity of hearing loss manifestations in the 
HIV population which may be conductive, sensorineural or central. Sensorineural hearing 
loss, which is irreversible, is the most well documented form of hearing loss in this 
population and ranges from 20% to 50%, occurring more frequently at higher frequencies 
(4000-8000Hz) than at lower frequencies (<400Hz) with a greater tendency towards a 
bilateral gradual onset versus rapid onset. 
16 
The hearing loss linked to HIV infection may 
be additive or even synergistic to that caused by aminoglycosides and capreomycin 




There is a large body of evidence reporting on the frequency of HIV associated hearing 
loss. One extensive review of the literature, reports that the prevalence of HIV associated 
hearing loss was generally low in some studies but in a South African HIV positive 
cohort, this figure was as high as 23%. 
16
 In another prospective study of 153 MDR-TB 
adults also conducted in South Africa, a hearing loss incidence of 39% amongst HIV 
positive subjects was observed. 
23
 This study also reported a more than threefold 


















Table of references referring to antiretroviral (ART) and hearing loss 
Year Ref no. Author Title and journal 
2000 24  Kakuda TN Pharmacology of nucleoside and nucleotide reverse transcriptase 
inhibitor-induced mitochondrial toxicity. Clinical Ther. 2000;  22(6): 
685-708.
2001 26 Simdon et al Ototoxicity associated with use of nucleoside analog reverse 
transcriptase inhibitors: A report of 3 possible cases and review of 
the literature. Clin Infect Dis. 2001.  32: 1623-1627.  
2002 27  Rey et al Severe  ototoxicity in a health care worker who received 
postexposure prophylaxis with stavudine, lamivudine and nevirapine 
after occupational exposure to HIV. Clin Infect Dis.   2002; 34 
(3):418-419. 
1997 28  Marra et al Hearing loss and antiretroviral therapy in patients infected with HIV-
1. Arch Neurol.  1997; 54(4): 407-410.
2006 29 Schouten et al A prospective study of hearing changes after beginning zidovudine 
or didanosine in HIV-1 treatment naïve people. BMC Infect Dis. 
2006;  6:28.   
5.3 Anti-retroviral therapy (ART) 
Anti-retroviral therapy (ART), in particular the nucleoside reverse transcriptase inhibitors
(NRTIs) contribute to hearing loss in HIV infected people through mitochondrial
toxicity.
24
 NRTIs form the backbone of the antiretroviral programme in South Africa;
25
hence this is a potentially significant risk factor for hearing loss in this population. Most
of the evidence supporting the association between NRTIs and hearing loss is based on
case reports and cross-sectional studies. The major limitations of these study designs
compared to prospective studies are that they provide weak evidence for causality,
temporality cannot be ascertained and they are subject to selection biases. Moreover, the
small sample size of case series makes it difficult to measure a relationship between the
exposure and the outcome. Nevertheless, the findings from these study designs are still
useful in helping us understand the relationship between NRTI use and hearing loss.  
In one case series, 3 patients aged >45 years with a history of noise-induced hearing loss  
reported worsening hearing impairment confirmed by audiometry after initiation of 
NRTIs such as lamivudine (3TC), stavudine (d4T), zidovudine (AZT) or didanosine. 
26
Another case report had similar findings when bilateral hearing loss was reported two 
weeks after a 23 year old female health care worker had received post exposure 
prophylaxis consisting of the NRTIs, d4T and 3TC. 
27











infected patients also reported NRTI use to be associated with hearing loss, 
28
 but this
finding was not replicated in a prospective observational study of  33 HIV-1 treatment 
naïve adults exposed to AZT or didanosine after controlling for confounders such as 
noise, immune status and age. 
29
 The lack of association in the prospective study may be
explained by the small sample size that was not sufficient to detect a significant 
difference. Alternatively, the results of the cross sectional study may be limited by the 
study design as temporality cannot be ascertained; hence hearing loss observed may have 
occurred before exposure to the NRTIs.  
5.4 Previous aminoglycoside therapy 
The aminoglycosides persist in the hair cells for extended periods (up to 6 months) after
completion of injectable therapy. 
11
This accumulation of aminoglycosides in addition to
the pre-existent damage of hair cells of the inner ear may explain the association between
previous aminoglycoside use and ototoxicity. There is limited literature reporting on the
association between previous aminoglycoside therapy and hearing loss. One editorial
states previous aminoglycoside therapy as a potential risk factor for hearing loss, 
7
whilst
a prospective study reported no relationship between previous exposure to
aminoglycosides and hearing loss. 
18
5.5 Genetic factors 
Genetic susceptibility has been identified as a strong predictor of ototoxicity.
7,11,30
A
mutation in the mitochondrial DNA A1555G or C1494T in the 12S rRNA gene increases
the susceptibility to aminoglycoside induced hearing loss. 
11
It is hypothesized that this
mutation causes the mitochondrial RNA gene in this region to resemble the bacterial
ribosomal RNA gene; thereby leading to increased binding of aminoglycosides leading to
altered protein synthesis of the mitochondria.
11
However; it has not been established
whether altered protein synthesis occurs within cochlear cells invivo, and why this
toxicity is limited to the cochlea and not the vestibular system. 
11
Data from three Chinese families reported that 15 members from those families with the 













Data pertaining to South Africa is scarce with one reported study describing a
family consisting of 18 members carrying the A1555G genetic mutation, and of these 11 
of 18 members developed hearing loss following exposure to streptomycin during 
tuberculosis treatment.  
31
5.6 Previous Tuberculosis disease and noise exposure 
There is only one reported study in the literature that describes the influence of previous
TB treatment on hearing thresholds. Brits et al. 
32
 conducted a retrospective study of gold
miners in Johannesburg, South Africa to determine this relationship. The study reported
that TB in itself was a risk factor for deterioration of hearing thresholds, particularly at
higher frequencies (4000-8000Hz) compared to no history of TB disease. However, 
multiple episodes of TB compared to no history of TB disease was the most significant
predictor of deterioration of hearing thresholds. 
32
This association was also attributed to
the complex interaction between TB and TB regimens that may be potentially ototoxic as
well as the associated risk profile including HIV infection. 
32
Acoustic exposure to high intensity noise or prolonged noise may potentiate cochlear
damage and subsequent administration of aminoglycosides is associated with synergistic
potentiation of cochlear damage that may lead to hearing loss. 
33
Brits et al,
demonstrated that noise exposed individuals (drillers) had higher hearing thresholds
compared to individuals not exposed to noise (administrative staff).  
32
6. Gaps in the literature and study rationale
Anecdotally, the prevalence of hearing loss in Khayelitsha is quite high and this is cause 
for concern. The literature on hearing loss frequency is somewhat inconsistent and is 
primarily from developed countries whilst data from the South Africa context is limited. 
There is also a lack of standard definitions of hearing loss across the various studies 
making meaningful comparisons difficult. Furthermore, the risk profile of DR-TB 
patients in South Africa is likely to be vastly different to that of individuals from the 
developed world. This is primarily due to the high HIV burden in South Africa compared 













  TB/HIV co infection is high in South Africa, and data specific to Khayelitsha
indicates an HIV/TB co infection rate of 60-70%. 
35
   These clinical differences in patient
populations make generalizability to the South African context challenging.  
In general, there is a scarcity of literature on risk factors for aminoglycoside induced 
hearing loss for long term use from both the developed and developing settings, in 
particular within South Africa. Furthermore, the available data is highly inconsistent, and 
some data is derived from low quality studies such as case series and case reports that 
provide weak evidence for causality. 
In light of this, there is a need to conduct research to determine the prevalence and
incidence as well as risk factors associated with aminoglycoside and capreomycin
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2. Abstract and key words
Introduction 
Treatment for drug-resistant tuberculosis (DR-TB) is longer and associated with more significant 
side-effects than drug susceptible TB. Second line injectable therapy using kanamycin, amikacin or 
capreomycin is associated with irreversible hearing loss. There is a scarcity of literature regarding 
the frequency of hearing loss as well as associated risk factors, particularly with long term use. This 
study aimed to determine the incidence and risk factors for hearing loss among patients receiving 
second line injectable drugs. 
Method 
This was a retrospective cohort of all DR-TB patients aged 18 years and above initiated on second
line injectable therapy in Khayelitsha clinics. DR-TB patients received a baseline audiometry screen
followed by monthly screening using pure tone audiometry. Hearing loss was defined as a loss of
hearing threshold of greater than 20 decibels at either high frequency (4000-8000Hz) or low
frequency (250-2000Hz).  Hearing loss was assessed at baseline and throughout treatment.  
Results 
From June 1, 2009 to December 2010, 238 subjects meeting eligibility criteria started DR-TB
treatment. Of these, 131 patients had at least one valid audiogram within 6 weeks of treatment
initiation, and 47 (35.9%) patients had baseline hearing loss. In multivariate analysis, older age and
HIV infection with CD4<100 cells/µl increased odds of baseline hearing loss. One hundred and
nine patients had a second audiogram to assess deterioration. Of these, 37 (33.9%) patients had
deterioration in hearing that was primarily mild but 9 patients (8.3%) had severe bilateral hearing
loss. In multivariate analysis, older age and baseline hearing loss predicted deterioration of hearing.
Conclusion 
Hearing loss at baseline and during treatment occurred frequently and was often severe. Increasing 
age and HIV infection with low CD4 count were associated with baseline hearing loss. Baseline 
hearing loss and older age predicted deterioration of hearing. 













South Africa  is a high tuberculosis (TB) burden country and was ranked third among the top 22 
high TB burden countries, with incident TB cases of between 0.40 million and 0.50 million per year 
and an incidence rate of 993 per 100,000 person years [1]. South Africa also has a high burden of 
drug resistant TB (DR-TB), in particular multi-drug resistant tuberculosis (MDR-TB) and 
extensively drug resistant tuberculosis (XDR-TB). WHO data from 2010, reported that South 
Africa had 10,085 reported cases of MDR-TB representing the second highest case notification 
amongst the 27 high burden MDR-TB countries [2]. 
MDR-TB (resistance to both rifampicin and isoniazid) poses a threat to effective TB control due to
the difficulties in diagnosis, the requirement for prolonged chemotherapy for up to two years, 
increased cost (up to 100 times costlier than treating drug sensitive TB) and the use of more toxic
second line drugs that are associated with increased adverse effects [2]
Studies have shown that at least 60% of patients on MDR-TB chemotherapy will experience an
adverse effect [3-5]. Nephrotoxicity and ototoxicity are the two major adverse effects associated
with the injectable second-line TB drugs, amin glycosides and capreomycin [6]. Nephrotoxicity is
reversible upon treatment discontinuation whilst ototoxicity is irreversible and is characterized by
impairment of hearing and/or balance [6]. The 2011 South African TB guidelines recommend
amikacin / kanamycin as the aminoglycosides of choice for the treatment of MDR-TB and
capreomycin for XDR-TB [7]. Amikacin, kanamycin and capreomycin are routinely used to treat
DR-TB in Khayelitsha, and are administered intramuscularly for a minimum duration of six months
as per national guidelines. 
A programme to provide decentralized care for DR-TB has been implemented in Khayelitsha since 
late 2007 [8].  Through this programme local clinicians have expressed concern about the observed 
prevalence of hearing loss associated with aminoglycosides and capreomycin. The literature on 
hearing loss frequency due to aminoglycosides and capreomycin is somewhat inconsistent with 
reported frequency in MDR-TB patients ranging from 6.7% [9]  up to 50% in other cohorts [3,10-
12]. Reported  risk factors for hearing loss include longer duration of injectable treatment, older 











noise exposure, presence of mitochondrial DNA mutations [6],  drug interactions with other 
ototoxic drugs[14],  HIV co-infection and use of anti-retroviral therapy in particular nucleoside 
reverse transcriptase inhibitors (NRTIs) [15].  
However, most of these data are derived from developed countries that have low HIV/TB co-
infection rates. South Africa has the largest HIV epidemic globally with an estimated 5.6 million
people infected with HIV in 2009 [16],  HIV co infection among TB patients in Khayelitsha is 70%, 
one of the highest in the country [8]. In addition, reported incidences of hearing loss in the literature
are inconsistent and there is a dearth of data relating to risk factors for hearing loss in long term
therapy such as for DR-TB. All these factors limit generalizability of existing data to many settings
with high HIV and MDR-TB treatment burden. In light of this, there is a need to determine the
incidence and risk factors associated with aminoglycoside and capreomycin induced hearing loss in
DR-TB patients in the South African context.   
Our aims of this study were to determine prevalence of hearing loss at treatment start and incidence
of hearing deterioration with treatment, to describe type and severity of hearing loss at start of
treatment and during DR-TB treatment; and to describe risk factors that are associated with hearing
loss at start of treatment and deterioration during DR-TB treatment.
4. Methods
4.1 Study Design and setting 
The retrospective cohort study was conducted with patients who received treatment at 11 clinics in
Khayelitsha but only one clinic was used to do audiometry screening. Khayelitsha is a peri-urban
sub-district within the Cape Town metropolitan area. The Khayelitsha decentralized DR-TB
programme was established in late 2007 in response to the high DR-TB burden in Khayelitsha and
lack of capacity of the local TB hospital to handle all DR-TB cases in a timely manner [8].  
4.2 Study population 
All adult patients aged 18 years and above with a diagnosis of  rifampicin resistant TB (defined as 
DR-TB) who were receiving intramuscular amikacin, kanamycin or capreomycin as part of the DR-
TB regimen were included in the cohort. In order to be included into the study, a patient must have 











was obtained from the University of Cape Town Ethics Committee and the study was approved by 
the City of Cape Town Research Committee. No informed consent was obtained from the study 
participants as audiometry testing was part of standard of care at Khayelitsha. 
4.3 Data Collection 
Upon initiation of DR-TB treatment, all demographic and clinical information was collected on a 
standardized form by the attending physician as standard of care. Thereafter, patients were referred 
to the audiometry testing centre based at one of the primary health care clinics in Khayelitsha. 
Hearing thresholds were measured objectively by an audiologist trained field worker using a pure
tone audiometer ( Interacoustics AS608). The screening test was conducted in a sound proof booth
at the following frequencies: 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz and 8000Hz. Prior to doing
the hearing assessment, the ear canal was examined using an otoscope for any signs of obstruction
such as inflammation, growths, foreign bodies or excessive cerumen to prevent obscured hearing
[17]. 
The reliability of the audiometry measurements was assessed using test retest reliability at every
frequency level for every audiogram whilst inter-rater reliability was conducted on a sub set of
audiograms. Test retest reliability was defined as consistent measurements made by the same rater. 
Hence, a valid audiogram was defined as one that did not have any ear(s) obstructed or one that was
classified as having good test-retest reliability.  
The first ever audiogram for each patient was classified relative to the start of DR-TB treatment:  i) 
Pre-treatment  audiograms were defined as audiograms taken within 10 days of initiating DR-TB 
treatment, prior to significant drug exposure ii) Early treatment audiograms were audiograms that 
were taken within 1.5 months of starting DR-TB treatment. Hearing loss that occurred within the 
first 1.5 months of treatment was referred to as baseline hearing loss. We used a less stringent 
definition that included audiograms taken up to 1.5 months into treatment because we had a limited 
number of individuals with pre-treatment audiograms. Furthermore, there was missing information with 
some of the variable which would have significantly reduced the precision of the estimates in the 












Patients were routinely followed up monthly until 2 months after the end of the injectable phase, 
typically a 6 to 8 month period. During the follow-up visits, ascertainment of hearing loss was 
measured in the manner similar to at baseline. All audiometry data collected at follow-up visits was 
compared with baseline data (if available) to ascertain whether deterioration had occurred. 
 
4.4 Outcome and explanatory variables 
The main outcome of interest was hearing loss.  Criteria from Gelfand (2009) were used to define 
hearing loss and severity but the criteria were modified in order to utilize fewer categories [18].  
The criteria used were: i) Normal hearing:  Average hearing threshold of ≤ 20 decibels at either the 
low or high frequency test frequencies ; ii) Mild hearing loss: Average hearing threshold of 
between 21 and 40 decibels at either the low or high test frequencies; iii) Moderate to severe 
hearing loss: Average hearing threshold of between 41 and 70 decibels at either low or high test 
frequencies and iv) Severe to profound hearing loss: Average hearing threshold of more than 70 
decibels across the low or high frequencies.  Severity of hearing loss was assessed using the better 
ear criteria which are based on WHO recommendations for assessment of hearing loss [19].  This 
means that hearing loss severity was categorized according to the ear with less severe hearing loss. 
 
Hearing loss was categorized into three frequencies: i) low frequency hearing loss (250 Hz to 
2000Hz ) ; ii) high frequency hearing loss (4000Hz and 8000 Hz) and; iii) mixed hearing loss- 
hearing loss occurring in both low and high frequencies.  
The measurement of hearing loss was done as follows: For low frequency hearing loss, averaging of  
hearing thresholds across 250 Hz, 500Hz, 1000Hz and 2000Hz was done for each ear separately at 
each visit; For high frequency hearing loss, averaging hearing thresholds across 4000 Hz and 8000 
Hz for each ear separately at each visit [20].  
Deterioration of hearing with treatment was assessed semi-qualitatively. This consisted of plotting 
each patient’s valid audiograms over the treatment period using calculated averages of hearing 
thresholds across low and high frequencies for each ear separately. This produced four line graphs 
per patient which were assessed by two independent assessors to determine the presence of hearing 
loss and to categorize severity based on definitions described previously. All discrepancies were 
resolved by consensus. Assessors were used  to assess the line graphs in preference of  a statistical 











The explanatory variables measured in this study were: age at DR-TB diagnosis, sex, history of 
aminoglycoside use, starting aminoglycoside dose, HIV status and CD4 count. The 
aminoglycosides (amikacin and kanamycin) and capreomycin were dosed as follows: i) 
weight<33kg- 15mg/kg/day; ii) weight between 33 and 50 kg- 500-750mg ; and iii) weight >50kg- 
1000mg.  
5. Statistical Analysis
The baseline characteristics of the cohort were described using medians and inter quartile ranges for
continuous variables with a skewed distribution and means and standard deviations for the normally
distributed data. Wilcoxon rank-sum test and t tests were used to assess differences between
continuous variables where appropriate. The categorical variables were assessed using Fishers
Exact Test and Chi-squared test where appropriate.    
Univariable and multivariable associations between hearing loss and explanatory variables were
assessed using logistic regression. A multivariable logistic model was used to test the association
between hearing loss and all the explanatory variables. The logistic regression models were built
using a priori assumptions from the literature on risk factors for hearing loss. Sex was also included
into the model as a potential confounder. Antiretroviral therapy could not be included into the final
models due to co-linearity between this variable and HIV status. Due to the low proportion of
patients with pre-treatment audiograms and the limited number of participants overall, restricting
the analysis to patients with confirmed absence of hearing loss prior to TB treatment resulted in a
substantially reduced sample siz with limited power to determine associations with new onset
hearing loss. We therefore looked for associations in models that were variously restricted to those
with pre-treatment or early treatment first audiograms, and with and without restriction to normal
hearing at the time of the first audiogram. This enabled us to confirm the consistency of
associations across models and limit potential bias due to the selected inclusion criteria. Statistical
analysis was conducted using STATA version 11.   
6. Results
From June 1, 2009 to 31, Dec 2010, 238 eligible adult patients were started on DR-TB treatment in 
Khayelitsha primary health care clinics.  Of those eligible for entry into the study, 175 (73.5%) 
patients had at least one valid audiogram but only 131 (74.9%) patients had at least one audiogram 












(Figure 1).  Sixty one (46.6%) and 70 (53.4%) patients had pre-treatment and early treatment 
audiograms respectively.  
Baseline characteristics 
There was no evidence of a difference between the patients with baseline audiogram within 1.5 
months of treatment start and those with no audiometry done with regards to demographic 
characteristics (weight, age, sex), clinical characteristics (HIV status and CD4 counts), treatment 
factors (type of injectable) and treatment history (previous aminoglycoside use and previous TB 
treatment) (Table 1). However, fewer patients with no audiometry were already receiving ART 
(26.5%) at DR-TB diagnosis compared to those who had baseline assessable within 1.5 months of 
DR-treatment initiation (48%). Overall, in both groups, kanamycin was the most frequently used 
injectable. 
Patients with a valid audiogram at baseline had median injection duration of 180 days, IQR [136-
199] and a total injectable dose of 119.3 g, IQR [80.7-134.3] (data not shown).With regards to 
screening, only 13 (9.9%) patients had a complete set of 6 audiograms done during treatment. 
Overall, patients had a median of 4 audiograms IQR [2-6] during treatment and the median time to 
first audiogram was 11 days, IQR [6-21] (Table 1). The median time between the first and second 
audiogram was 32 days, IQR [20-42]. 
Frequency, type and severity of baseline hearing loss at treatment initiation 
The prevalence of baseline hearing loss relating to pre-treatment (31.2%; 95% CI: 20-44.3) and 
early treatment audiograms (40%; 95%CI: 28.5-52.4) (p=0.292) was similar; therefore we 
combined both categories.  Of 131 adults who had a valid audiogram within 1.5 months treatment 
start, 47 (35.9%) had baseline hearing loss (Figure 2). Mixed hearing loss occurred more 
frequently, 29 (22.1%) versus 18 (13.7%) patients with high frequency hearing loss. Overall, 25.2% 
(33/131) and 5.3% (7/131) of patients had mild and severe forms of hearing loss respectively. Seven 
patients (5.3%) had a combination of mild loss at low frequencies and severe loss at higher 














Frequency, type and severity of hearing deterioration during DR-TB treatment 
 Of 131 patients with a valid audiogram within 1.5 months of treatment start, 109 (83.2%) patients 
had at least two audiograms to assess deterioration (Figure 3). Of these, 38 (34.9%) had baseline 
hearing loss. In total, 37 (33.9%) patients had deterioration in hearing during DR-TB treatment that 
was bilateral in nature. Of the 71 subjects with no baseline hearing loss, only 12 (16.9%) patients 
had deterioration in hearing with treatment compared to 65.8% (25/38) in the group with baseline 
hearing loss. 
Overall, hearing loss was predominately mixed in nature, 22% (24/109) patients had mixed loss
versus 9.2% (10/109) and 2.8% (3/109) with high and low frequency loss respectively (Figure. 3)
A similar pattern of deterioration in hearing was seen in patients with baseline hearing impairment. 
However, patients with normal hearing at treatment start, (n=71) had primarily deterioration in the
high frequency ranges only.
Mild bilateral hearing loss occurred most frequently in the entire group with 20.2% (22/109) with
mild hearing loss and 8.3% (9/109) patients with severe forms of bilateral hearing loss. Six patients
(5.5%) had a combination of mild and severe loss. Mild hearing loss occurred more frequently in
patients with normal hearing at treatment start whilst severe hearing impairment was more common
amongst those with baseline hearing loss. 
Univariable and multivariable analysis of factors associated with baseline hearing loss
In the univariable analysis, only increasing age (OR 2.2, 95% CI: 1.4-3.2) was associated with
increased odds of baseline hearing loss within 1.5 months of treatment start (Table 2). In the
multivariable data analysis, older age (OR 2.4; 95%CI: 1.5-3.8) and HIV infection and severity
(CD4 count<100 cells/µl) (OR 4.1; 95%CI: 1.2-13.7)  increased odds for baseline hearing loss. 
Male sex, aminoglycoside history and positive HIV status did not predict hearing loss during DR-
TB treatment in all three models (Table 3). Across a range of inclusion criteria for analyses of 
hearing deterioration (Table 3), there was evidence in both univariable and multivariable analyses 
in support of both age at diagnosis and baseline hearing loss being associated with deterioration. 
For example, amongst patients with normal pre-treatment or early treatment audiogram (n=71), 
increasing age for each ten year increment in age was associated with an increased odds of 












(OR 3.1; 95% CI: 1.2-7.9) (Table 3). Baseline hearing loss amongst patients with a pre-treatment or 












We report a high prevalence of baseline hearing loss (35.9%) and deterioration of hearing during 
DR-TB treatment (34%) that was primarily mixed and mild in severity. New onset hearing loss also 
occurred frequently, mostly affecting high frequencies and was mild in severity. In multivariable 
analysis, patients with older age and severe HIV infection with CD4<100 cells/ul were more likely 
to have baseline hearing loss. Amongst patients with a second audiogram to assess deterioration, 
older age and baseline hearing loss predicted hearing deterioration. 
Hearing loss at first audiogram 
We report an initial hearing loss prevalence of 35.9% that was bilateral, predominately mixed and
mild in severity. In contrast, a study by Peloquin et al [13], reported a markedly lower prevalence
of 5.7% of hearing loss at baseline. Differences in clinical characteristics, in particular HIV
prevalence, a well-documented hearing loss risk factor [21-23], may account for the differences as
the study by Peloquin et al was based in the US.
In multivariable analysis, increasing age and severe HIV disease (CD4<100 cells/µl) were
associated with an increased odds of baseline hearing loss. Previous studies have not reported on
the relationship between baseline characteristics and pre-existing hearing loss. Theoretical
hypotheses suggest that a reduction in hair cells in the cochlea and/or reduction in endogenous
protective mechanisms that occurs in older age [24] and HIV associated opportunistic infections
such as otitis media associated with low CD4 counts increase the susceptibility for hearing loss
[15].
Deterioration of hearing on treatment
Overall, we reported a cumulative incidence of 34% in deterioration of hearing. This is higher than 
estimates from previous studies primarily from developed settings that report hearing loss 
frequencies ranging from 6.7% to 21.3% [3,9,10].  
We observed a new-onset hearing loss cumulative incidence of 16.9% during treatment in patients 
with normal hearing at first audiogram that mostly affected the high frequencies and was mild in 
severity. This pattern of selectively affecting high frequencies first before affecting conversational 
frequencies (low frequencies) is consistent with the mechanism of aminoglycoside induced hearing 
loss [14,25,26].
 











18.75%, that was predominately high frequency loss [11].  However, our findings contrast with 
another South African DR-TB cohort that reported an incidence of  58% over a 3 month period 
[23],
 
as well as data from developed settings that reported incidences ranging from 28% to 55% 
during DR-TB treatment [27-29].  These differences could be in part due to the inconsistent 
definitions of hearing loss across the studies. In particular, hearing loss definitions in previous 
studies included unilateral loss whilst our hearing loss definition restricted it to bilateral loss only. 
In addition, our cohort did not have regular audiometry monitoring possibly underestimating the 
true extent of hearing loss. 
Theoretically, pre-existing hearing loss leads to deterioration of hearing due to fewer hair cells at
the treatment start or a reduction in endogenous protective mechanisms [24,25]. Deterioration of
hearing amongst those with baseline hearing loss occurred frequently in our cohort. In addition,
multivariable analysis showed a positive association between baseline hearing loss and deterioration
of hearing that has not been observed in a previously reported study of short term aminoglycoside
use [30].
We observed that increasing age predicted new onset hearing loss, a finding that has been reported
in previous DR-TB studies [13,27,28]. However, we failed to show an association between HIV
infection and hearing loss during DR-TB treatment. This finding was unexpected as we had a high
HIV prevalence and low median CD4 count at treatment start. This also conflicted with data from
another Cape Town DR-TB cohort that demonstrated a strong positive association between HIV
infection and development of hearing loss, [23] but this study did not control for potential
confounders such as age and past aminoglycoside use. 
Strengths and limitations
Our study findings are limited by missing information in some variables and small sample size that 
decreased the precision of estimates.  In addition, audiograms were conducted at irregular intervals, 
thereby limiting our ability to measure timing of hearing loss; hence variables such as injection 
duration and total aminoglycoside dose could not be included into the analyses. Our results may 
also have been confounded by variables such as exposure to noise and concomitant ototoxic drugs 
that were not measured. We did not use a strict definition of baseline, and included audiograms that 
had been taken up to 1.5 months into treatment; hence baseline hearing loss may have been 











interpretation of our results as we may have underestimated the true incidence of hearing loss 
during DR-TB treatment as we considered individuals with an audiogram taken at 1.5 months as 
having existed prior to treatment start. The use of the better ear criteria also limited the analysis to 
bilateral hearing loss only, whilst previous studies include unilateral loss in their hearing loss 
definition. Another major limitation is that the audiometry tests are screening tests and we did not 
have any diagnostic hearing tests done by an audiologist to confirm whether hearing loss was 
sensorineural. Consequently, the true extent of hearing loss may have been overestimated due to 
other causes or underestimated as pure tone audiometry relies on the patient’s ability to respond to 
hearing stimuli.  Nonetheless, the findings of this study are strengthened by inclusion of all DR-TB 
patients, minimal selection bias in excluding subjects without audiometry, use of routine data, use 
of an objective measure to assess hearing loss as well as the rigorous method of assessing validity 
of audiograms. 
8. Conclusion
The occurrence of hearing loss in DR-TB patients at baseline and deterioration during DR-TB 
treatment is common and often severe. Hearing loss on the first audiogram predicted subsequent
deterioration of hearing. This finding underscores the value of conducting more frequent pre-
treatment/ early treatment audiograms in patients commencing injectable therapy in order to
minimize potential deterioration and implement prevention strategies such as dose reduction. There
is limited data on hearing loss during long term aminoglycoside use from developing settings. More
studies that measure exposure to ototoxic medication and noise exposure as well as measure timing
of the onset of hearing deterioration are needed. Furthermore, studies on measures to avert
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*This refers to patients who did not have a pre-treatment audiogram or an early treatment
audiogram. 
Patients with no valid audiograms (n=63) 
52 patients with no audiometry done 
11 patients with obstructed audiograms 
Patients with at least 1 valid audiogram 
n= 175 
*Patients with no audiogram




Early treatment audiograms 
n= 70 
Figure 1. Flow chart of patients starting DR-TB treatment in Khayelitsha and those
eligible for analysis.













*This reflects a combination of severity from low and high frequencies.
First audiogram within 1.5 
months of treatment start 
n=131 
 Baseline hearing 
impairment n=47 
(35.9%) 
Mixed hearing loss 
n=29 (61.7%) 
High frequency 













Figure 2. Frequency, type and severity of baseline hearing loss in patients initiated 




































treatment n=12 (16.9%) 
 
No deterioration with 











Subjects with at least 2 audiograms (including pre-
treatment and early treatment audiogram) to assess 
deterioration (n=109) 
No hearing loss at baseline 
n=71 (65.1%) 

















Mild high frequency (n=7) 
Mild low frequency (n=2) 
 
Mixed loss n=3 
Mild ( n=2) 
Severe-profound (n=1) 
Figure 3. Frequency, type and severity of deterioration in hearing in 











Table 1. Baseline characteristics of patients with a valid baseline audiogram compared to those 
with no audiometry conducted. 
Baseline characteristics No  audiometry 
(n=52) 
Baseline audiogram within 
1.5 months of treatment 
start (n=131) 
P value* 
Weight (kg),  mean weight± sd 59± 8.5 55±9.7 0.13 
Age, median years [IQR] 35.6 [28.7-39.9] 34.4 [27.6-40.7] 0.47 
Sex 
Male 31 (59.6%) 65 (49.6%) 0.22 
HIV status 
Positive 36 (69.2%) 98 (74.8%) 0.29 
Negative 14 (26.9%) 32 (24.4%) 
Unknown 2 (3.8%) 1 (0.8%) 
CD4 , median cells/µl [IQR] 122 [48-174] 133 [54-228] 0.29 
On ART at  diagnosis€ 
Yes 9 (26.5%) 47 (48.0%) 0.03 
Previous TB treatment# 
Previous 1st line treatment 31 (60.8%) 86 (66.7%) 0.3 
Previous 2nd line treatment 8 (15.7%) 10 (7.8%) 
No TB treatment 12 (23.5%) 33 (25.6%) 
Aminoglycoside history¥ 
Yes 17 (42.5%) 48 (44.0%) 0.87 
Type of injectable 
Kanamycin 51 (98.1%) 114 (87.0%) 0.07 
Amikacin 1 (1.9%) 15 (11.5%) 
Capreomycin 0 2 (1.5%) 
Number of audiograms, median audiogram [IQR] - 4 [2-6] 
Time to first audiogram, median days [IQR] - 11 [6-21] 
ART- antiretroviral therapy; sd- standard deviation; IQR- interquartile range
*Wilcoxon rank sum test and t test for continuous variables, chi square tests and Fishers exact test
where applicable for categorical variables.
€ Two patients in the no audiometry group had missing information. 
# One patient in the no audiometry group and 2 patients with a baseline audiogram had missing 
information. 












Table 2. Univariable and multivariable analyses of risk factors for baseline hearing loss in patients 
initiating DR-TB treatment. 
*N=131 Univariable analysis Multivariable analysis 
Baseline characteristic Odds ratio 
(OR) 
95%CI Odds ratio 
(OR) 
95% CI 
Age at diagnosis (yrs)-per 10 years 2.2 (1.4-3.2) 2.4 (1.5-3.8) 
Male sex 1.6 (0.8-3.4) 1.4 (0.6-3.2) 
Aminoglycoside history 
No 
Yes 0.7 (0.3-1.5) 0.8 (0.3-1.8) 
HIV & CD4 category 
HIV negative (reference) 1.0 1.0 
HIV positive &CD4≥100 1.1 (0.4-2.7) 2.5 (0.7-7.3) 
HIV positive &CD4 <100 2.0 (0.7-5.2) 4.1 (1.2-13.7)
*The 131 patients refers to those who had at least one audiogram done (pre-treatment or early












Table 3. Associations with deterioration in hearing threshold on treatment categorized by first audiogram status 
 
 
*Pre-treatment AG available 
(n=53) 
#Normal first AG pre-treatment 
or early treatment (n=71) 
¥Any first AG pre-treatment or early 
treatment AG 
(n=109) 
 Univariable Multivariable Univariable Multivariable Univariable Multivariable 
 OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI OR 95%CI 
Age at diagnosis (per 10 
years) 
1.5 (0.8-2.8) 1.4 (0.6-2.9) 2.5 (1.1-5.7) 3.1 (1.2-7.9) 1.9 (1.2-2.9) 1.3 (0.8-2.3) 
Male sex 1.1 (0.3-3.4) 0.5 (0.1-2.3) 0.7 (0.2-2.7) 0.2 (0.0-1.4) 1.2 (0.6-2.8) 0.8 (0.3-2.2) 
Aminoglycoside history 1.1 (0.3-3.7) 1.8 (0.4-7.6) 2.2 (0.5-8.0) 2.2 (0.5-1.0) 1.1 (0.5-2.4) 1.2 (0.5-3.3) 
Aminoglycoside dose (per 
100mg) 
0.8 (0.6-1.2) 0.7 (0.5-1.1) 0.8 (0.5-1.2) 0.7 (0.4-1.1) 0.8 (0.6-1.0) 0.8 (0.6-1.1) 
HIV status & CD4 count 
(cells/µl) 
            
HIV negative (reference) 1.0  1  1  1  1  1  
HIV positive & CD4≥100 0.5 (0.1-1.7) 0.4 (0.1-1.8) 0.5 (0.1-2.3) 0.4 (0.1-2.1) 0.5 (0.2-1.3) 0.4 (0.1-1.5) 
HIV positive and 
CD4<100 
0.3 (0.1-2.0) 0.2 (0.0-1.4) 0.6 (0.1-3.8) 0.2 (0.0-2.6) 0.7 (0.2-2.1) 0.4 (0.1-1.7) 
Baseline hearing loss 3.3 (0.9-12.1) 3.7 (0.7-18.1)     9.5 (3.8-23.6) 8.5 (3.0-24.1) 
AG- audiogram; OR- Odds ratio   
*Any pre-treatment audiogram plus a second audiogram available to assess deterioration. This included patients with hearing loss at 
baseline, so adjustment for baseline hearing loss included into the model 
# Only patients with a normal pre-treatment or normal early treatment audiogram plus a second audiogram to assess deterioration 
 ¥ Any patient with a pre-treatment or an early treatment audiogram plus a second audiogram to assess deterioration. This included patients 

















































DOB: Pt. Telephone No. 
Referral 
Clinic: 
Date referral made: 
Referral Doctor: Folder No. 
Reason for 
Referral 
Baseline 3 month Tx 6 month Tx Other: 
1 month Tx 4 month Tx 7 month Tx 
2 month Tx 5 month Tx 8 month Tx 
Date Current DR TB Treatment 
Started: 
Patients current wt. 












Previous Treatment with Streptomycin, Kanamycin, Amikacin, Capreomycin 
Streptomycin 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Kanamycin 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________
Dose _________________ 







Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Capreomycin 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Date start _____________ 
Date stop _____________ 
Dose _________________ 
Previous Audiometry € Yes € No Date: Where? 
Results: € Normal € Abnormal
Attach results of previous audiogram if not done at Ubuntu clinic 
Clinical Assessment • Patient complains of poor hearing
• Family History of hearing loss to TB medication








Serum Creatinine: Date serum creatinine: 
Appointment Date for 
Audiometry: 



















DOB: Pt. Telephone No. 
Referral Clinic: Date referral made: 
Reason for 
Referral 
Baseline 3 month Tx 6 month Tx Other: 
1 month Tx 4 month Tx 7 month Tx 
2 month Tx 5 month Tx 8 month Tx 
Questions for Patient: 
• Ringing in ears
• Hearing loss




• Family history: hearing loss
from TB meds 
•









Date of Test: Name of Screener: Test Reliability: € Good
€ Poor
Key Response No-Response 
Right (red) O O 









Ear Canal obstructed  with ____________________________________________ 
Abnormal ear drum (describe)__________________________________________ 
Abnormal audiogram  



























High pitch Low pitch 
Loud 
Soft 














If yes to any of the above, advise the patient to see his/her doctor urgently (not to wait until their next scheduled doctor’s appt. 
€ Yes € No Patient referred to doctor urgently  ( if yes, put red sticker on this form) 
 
 Follow up appt:   
 















































































Appendix 3: Line graph of audiograms representing severe hearing loss 











 Appendix 4: University of Cape Town ethics approval letter 
10 December 2010  University of Cape Town 
HREC REF: 503/2010 
Ms C Njuguna 
c/o Prof ABoulle 
Public Health & Family Medicine 
Dear Ms Njuguna 
PROJECT TITLE: RISK FACTORS THAT PREDISPOSE TO AMINOGLYCOSJDE/CAPREOMYCIN
INDUCED HEARING LOSS IN ADULT PATIENTS RECEIVING TREATMENT FOR MULTI-DRUG 
RESISTANT TUBERCULOSIS (MDR-TB) AND EXTENSIVE DRUG RESISTANT TUBERCULOSIS (XDR-
TB) IN KHAYELITSHA, WESTERN CAPE 
Thank you for submitting your new study to the Faculty of Health Sciences Human Research Ethics Committee. Thank
you for your response to the queries raised by the HREC. 
It is a pleasure to inform you that the FHS HREC has formally approved the above-mentioned study. 
Approval is granted for one year until 15 December 2011.
Please send us an annual progress report (website form FHS 016) if your research continues beyond the approval period.
Alternatively, please send us a brief summary of your findings so that we can close the research file. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal investigator. Please
quote the REC. REF in all your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN 












Appendix 4: City Health study approval 
CITY   HEALTH  — Specialised Health 
2011-05-10 
re: Research    Request: Risk  factors  that  predispose  to 
aminoglycoslde/capreomycin induced hearing loss in adult patients receiving treatment for multi-drug 
resistant tuberculosis (MDR-TB) and extensive drug resistant tuberculosis (XDR-TB) In Khayelitsha, Western 
Cape (ID HO: 10239) 
Dear Dr Cox 
Permission has been granted to do your research as per your protocol. 
 Khayelitsha Sub District 
 Contact People: Dr. V de Azevedo (Sub District Manager) 
 Tel: (021) 360 1258/083 629 3344 
 Mr Mhulbulwana (Head: PHC & Programmes) 
 Tel: (021) 360-1153/ 082 715 0147 
Please note the following: 
1 Ail individual patient information obtained must be kept confidential.
2. Access to the clinic and its patients must be arranged with the relevant Manager such that
normal activities are not disrupted. 
3. A copy of the final report must be sent to the City Health Head Office, P O Box 2815 Cape
Town 8001, within 3 months of its completion and feedback must also be given to the
clinics involved. 
4. Your project has been given an ID Number (10239).    Please use this in any future
correspondence with us. 
Thank you for your co-operation and please contact me if you require any further information or assistance. 
Yours sincerely 
DR G H VISSER 
MANAGER: SPECIALISED HEALTH 











Appendix 5- PLOS ONE AUTHOR INSTRUCTIONS 
PLOS ONE Manuscript Guidelines 
http://www.plosone.org/static/guidelines 
1. Format Requirements
PLOS ONE does not consider presubmission inquiries. All submissions should be prepared with the following 
files: 
•Cover letter
•Manuscript, including tables and figure legends
•Figures (guidelines for preparing figures can be found at the Figure and Table Guidelines)
Prior to submission, authors who believe their manuscripts would benefit from professional editing are
encouraged to use language-editing and copyediting services. Obtaining this service is the responsibility of
the author, and should be done before initial submission. These services can be found on the web using
search terms like "scientific editing service" or "manuscript editing servic ." Submissions are not copyedited
before publication.
Submissions that do not meet the PLOS ONE Publication Criterion for language standards may be 
1.1 Cover Letter
You should supply an approximately one page cover letter that:
•Concisely summarizes why your paper is a valuable addition to the scientific literature 
•Briefly relates your study to previously published work
•Specifies the type of article you are submitting (for example, research article, systematic review, meta-
analysis, clinical trial) 
•Describes any prior interactions with PLOS regarding the submitted manuscript
•Suggests appropriate PLOS ONE Academic Editors to handle your manuscript (view a complete listing of
our academic editors) 
•Lists any recommended or opposed reviewers
Your cover letter should not include requests to reduce or waive publication fees. Should your manuscript 
be accepted, you will have the opportunity to include your requests at that time. See PLOS ONE Editorial 
Policy for more information regarding publication fees.  
1.2 Manuscript Organization 
PLOS ONE considers manuscripts of any length. There are no explicit restrictions for the number of words, 
figures, or the length of the supporting information, although we encourage a concise and accessible 











All manuscripts should include line numbers and page numbers. 











Figures should not be included in the main manuscript file. Each figure must be prepared and submitted as
an individual file. Find more information about preparing figures here.The title, authors, and affiliations
should all be included on a title page as the first page of the manuscript file. There are no explicit
requirements for section organization between these beginning and ending sections. Articles may be
organized in different ways and with different section titles, according to the authors' preference. In most





PLOS ONE has no specific requirements for the order of these sections, and in some cases it may be 
appropriate to combine sections. Guidelines for individual sections can be found below. Abbreviations 
should be kept to a minimum and defined upon first use in the text. Non-standard abbreviations should not 
be used unless they appear at least three times in the text.  
Standardized nomenclature should be used as appropriate, including appropriate usage of species names 
and SI units. 
1.3 Manuscript File Type Requirements 
Authors may submit their manuscript files in Word (as .doc or .docx), LaTeX (as .pdf), or RTF format. Only 











LaTeX Submissions. If you would like to submit your manuscript using LaTeX, you must author your article 
using the PLOS ONE LaTeX template and BibTeX style sheet. Articles prepared in LaTeX may be submitted in 
PDF format for use during the review process. After acceptance, however, .tex files and formatting 
information will be required as a zipped file. Please consult our LaTeX guidelines for a list of what will be 
required. 
Submissions with equations. If your manuscript is or will be in .docx format and contains equations, you 
must follow the instructions below to make sure that your equations are editable when the file enters 
production. 
If you have not yet composed your article, you can ensure that the equations in your .docx file remain
editable in .doc by enabling "Compatibility Mode" before you begin. To do this, open a new document and
save as Word 97-2003 (*.doc). Several features of Word 2007/10 will now be inactive, including the built-in
equation editing tool. You can insert equations in one of the two ways listed below.
If you have already composed your article as .docx and used its built-in equation editing tool, your
equations will become images when the file is saved down to .doc. To resolve this problem, re-key your
equations in one of the two following ways.
1. Use MathType to create the equation (recommended)
2. Go to Insert > Object > Microsoft Equation 3.0 and create the equation
If, when saving your final document, you see a message saying "Equations will be converted to images,"
your equations are no longer editable and PLoS will not be able to accept your file.
2 Guidelines for Standard Sections 
2.1 Title 
Manuscripts must be submitted with both a full title and a short title, which will appear at the top of the 
PDF upon publication if accepted. Only the full title should be included in the manuscript file; the short title 
will be entered during the online submission process.
The full title must be 150 characters or fewer. It should be specific, descriptive, concise, and 
comprehensible to readers outside the subject field. Avoid abbreviations if possible. Where appropriate, 
authors should include the species or model system used (for biological papers) or type of study design (for 
clinical papers). 
Examples: 
•Impact of Cigarette Smoke Exposure on Innate Immunity: A Caenorhabditis elegans Model
•Solar Drinking Water Disinfection (SODIS) to Reduce Childhood Diarrhoea in Rural Bolivia: A Cluster-
Randomized, Controlled Trial  











All author names should be listed in the following order: 
•First names (or initials, if used),
•Middle names (or initials, if used), and
•Last names (surname, family name)
Each author should list an associated department, university, or organizational affiliation and its location, 
including city, state/province (if applicable), and country. If the article has been submitted on behalf of a 
consortium, all author names and affiliations should be listed at the end of the article. 
This information cannot be changed after initial submission, so please ensure that it is correct.
To qualify for authorship, a researcher should contribute to all of the following:
1.Conception and design of the work, acquisition of data, or analysis and interpretation of data
2.Drafting the article or revising it critically for important intellectual content 
3.Final approval of the version to be published
All persons designated as authors should qualify for authorship, and all those who qualify should be listed.
Each author must have participated sufficiently in the work to take public responsibility for appropriate 
portions of the content. Those who contributed to the work but do not qualify for authorship should be
listed in the acknowledgments. When a large group or center has conducted the work, the author list 
should include the individuals whose contributions meet the criteria defined above, as well as the group
name.
One author should be designated as the corresponding author, and his or her email address or other
contact information should be included on the manuscript cover page. This information will be published
with the article if accepted.
See the PLOS ONE Editorial Policy regarding authorship criteria for more information.
2.2 Abstract
The abstract should:
•Describe the main objective(s) of the study
•Explain how the study was done, including any model organisms used, without methodological detail
•Summarize the most important results and their significance
•Not exceed 300 words















The introduction should:  
•Provide background that puts the manuscript into context and allows readers outside the field to 
understand the purpose and significance of the study  
•Define the problem addressed and why it is important 
•Include a brief review of the key literature 
•Note any relevant controversies or disagreements in the field 
•Conclude with a brief statement of the overall aim of the work and a comment about whether that aim 
was achieved  
2.4 Materials and Methods 
This section should provide enough detail to allow suitably skilled investigators to fully replicate your study. 
Specific information and/or protocols for new methods should be included in detail. If materials, methods, 
and protocols are well established, authors may cite articles where those protocols are described in detail, 
but the submission should include sufficient information to be understood independent of these 
references.  
We encourage authors to submit detailed protocols for newer or less well-established methods as 
Supporting Information. These are published online only, but are linked to the article and are fully 
searchable. Further information about formatting Supporting Information files, can be found here. 
Methods sections of papers on research using human or animal subjects and/or tissue or field sampling 
must include required ethics statements. See the Reporting Guidelines for human research, clinical trials, 
animal research, and observational and field studies for more information.  
Methods sections of papers with data that should be deposited in a publicly available database should 
specify where the data have been deposited and provide the relevant accession numbers and version 
numbers, if appropriate. Accession numbers should be provided in parentheses after the entity on first use. 
If the accession numbers have not yet been obtained at the time of submission, please state that they will 
be provided during review. They must be provided prior to publication.  
Methods sections of papers using cell lines must state the origin of the cell lines used. See the Reporting 
Guidelines for cell line research for more information.  
Methods sections of papers adding new taxon names to the literature must follow the Reporting Guidelines 
below for a new zoological taxon, botanical taxon, or fungal taxon.  
2.5 Results, Discussion and Conclusion 
These sections may all be separate, or may be combined to create a mixed Results/Discussion section 
(commonly labeled "Results and Discussion") or a mixed Discussion/Conclusions section (commonly labelled 
"Discussion"). These sections may be further divided into subsections, each with a concise subheading, as 












Together, these sections should describe the results of the experiments, the interpretation of these results, 
and the conclusions that can be drawn. Authors should explain how the results relate to the hypothesis 
presented as the basis of the study and provide a succinct explanation of the implications of the findings, 
particularly in relation to previous related studies and potential future directions for research.  
PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should avoid 
overstating their conclusions. See the PLOS ONE Publication Criteria for more information. 
2.6 Back to top Acknowledgments 
People who contributed to the work but do not fit the PLOS ONE authorship criteria should be listed in the 
acknowledgments, along with their contributions. You must ensure that anyone named in the 
acknowledgments agrees to being so named.  
Funding sources should not be included in the acknowledgments, or anywhere in the manuscript file. You 
will provide this information during the manuscript submission process. 
2.7 Back to top References 
Only published or accepted manuscripts should be included in the reference list. Manuscripts that have 
been submitted but not yet accepted should not be cited. Limited citation of unpublished work should be 
included in the body of the text only as “unpublished data.” 
References must be listed at the end of the manuscript and numbered in the order that they appear in the 
text. In the text, citations should be indicated by the reference number in brackets. Journal name 
abbreviations should be those found in the NCBI databases. A number of reference software companies 
supply PLOS style files (e.g., Reference Manager, EndNote).  
Proper formatting of the references is crucial; some examples are shown below. 
•Published papers. Hou WR, Hou YL, Wu GF, Song Y, Su XL, et al. (2011) cDNA, genomic sequence cloning 
and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet 
Mol Res 10: 1576-1588. 
Note: Use of a DOI number for the full-text article is acceptable as an alternative to or in addition to 
traditional volume and page numbers.  
•Accepted, unpublished papers. Same as above, but “In press” appears instead of the page numbers.  
•Electronic journal articles. Huynen MMTE, Martens P, Hilderlink HBM (2005) The health impacts of 
globalisation: a conceptual framework. Global Health 1: 14. Available: 
http://www.globalizationandhealth.com/content/1/1/14. Accessed 25 January 2012.  
•Books. Bates B (1992) Bargaining for life: A social history of tuberculosis. Philadelphia: University of 
Pennsylvania Press. 435 p.  
•Book chapters Hansen B (1991) New York City epidemics and history for the public. In: Harden VA, Risse 
GB, editors. AIDS and the historian. Bethesda: National Institutes of Health. pp. 21-28.  











Tables submitted for publication should be included at the very end of the article file (.doc, .rtf, .tex). 
Supporting Information tables should be submitted as separate files in any of the following formats 
(although authors should aim to ensure that the file type is most appropriate to the information displayed): 
Word (.doc), Excel (.xls), PDF, PPT, JPG, EPS, or TIFF. 
Title and Footnotes 
Each table needs a concise title of no more than one sentence, placed above the table with the table 
number (e.g., Table 1). The legend and footnotes should be placed below the table. Footnotes may be used 
to explain abbreviations. 
Specifications 
Tables that do not conform to the following requirements may give unintended results when published. 
Problems may include the movement of data (rows or columns), loss of spacing, or disorganization of 
headings. Note: Multi-part tables with varying numbers of columns or multiple footnote sections should be 
divided and renumbered as separate tables. 
In the published version, tables will be formatted in PLOS style. This includes alternate row shading, content 
left-aligned in cells, title above the table and legend/footnotes below the table.
Tables must: 
◦Be cell-based (e.g., created in Word with Tables tool (preferred) or in Excel).
◦Be editable (i.e., not a graphic object).
◦Have heading/subheading levels in separate columns.
◦Be no larger than one printed page (7 in x 9.5 in). Larger tables can be published as online supporting
information. Note: some wide tables may be printed sideways in the PDF. 
Tables must not: 
◦Use returns or tabs within a cell.
◦Have color or shading.
◦Use lines, rules, or borders.
◦Contain spaces within cells to align text.
◦Have vertically merged cells; horizontally merged cells are fine.
◦Have inserted text boxes or pictures.
◦Have tables within tables.












Figures should not be included in the manuscript file, but figure legends should be. Guidelines for preparing 
figures can be found here. 
Figure legends should describe the key messages of a figure. Legends should have a short title of 15 words 
or less. The full legend should have a description of the figure and allow readers to understand the figure 
without referring to the text. The legend itself should be succinct, avoid lengthy descriptions of methods, 
and define all non-standard symbols and abbreviations.  
Further information about figure legends can be found in the Figure Guidelines. 
2.9 Figure preparation 
Figures should not be included in the manuscript file, but figure legends should be. Guidelines for preparing 
figures can be found here. Figure legends should describe the key messages of a figure. Legends should 
have a short title of 15 words or less. The full legend should have a description of the figure and allow 
readers to understand the figure without referring to the text. The legend itself should be succinct, avoid 
lengthy descriptions of methods, and define all non-standard symbols and abbreviations. 
File Size 
Individual figure files should not exceed 10 MB. If you are having trouble reducing the size of your files,
refer to the section below titled Reduce TIFF File Size with LZW Compression.
Figure Quality 
A figure that looks good on screen may not be at optimal resolution. Test your figures by sizing them to
their intended dimensions (see Quick Reference: Dimensions) and then printing them on your personal
printer. The online version should look relatively similar to the personal-printer copy: it should not look
fuzzy, jagged, pixilated, or grainy at the intended print size.
Note: The quality of your figures will be only as good as the lowest-resolution element placed in them. In
other words, if you created a 72 ppi line graph and placed in it a 300 ppi TIFF, it will be upsampled, resulting
in it looking blurred, jagged, or pixelated.
Figure Format 
Figures for publication must only be submitted in high-resolution TIFF or EPS format. Some figure types 
should be submitted in TIFF only (see Figure Types below). If you have not made any annotations to your 
image, and you have a high-quality TIFF, there is no need to submit it embedded in an EPS, as there will be 
no increase in quality as a result. See How To: Convert Other File Types to TIFF below for more information 
on converting figure files to TIFF. 
Color Mode 
Figures containing color should be saved in either Grayscale or RGB (millions of colors), rather than Indexed 
Color, CMYK or any other color space. Grayscale or RGB files should be saved with a bit depth of 8 bits per 












TIFF files with multiple layers are not an accepted format for figures. Please make sure you provide us with 
a flattened version of your file. To flatten a layered TIFF file, open your figure in Photoshop. From the menu 
bar select Layer/Flatten Image and save the file. See also Combination Figures, below. 
Multi-Page TIFFS 
TIFF files with multiple pages are not an accepted format for figures. 
Background Color 
Create your figures using a white background. If you create figures using a transparent background, the 
figures may not display well in the online format. 
Lines, Rules, and Strokes 
Lines should be at least 0.5 point and no more than 1.5 point in order to reproduce well in a PDF file or web
format.
Figure Dimensions 
Figures for publication will be sized to fit 1, 1.5, or 2 columns of the final printable PDF of the article.
Dimensions will also depend on the article type. Please follow the sizing recommendations below for your
original submission to create high-quality, appropriately sized figures. See Figure Types below for
descriptions and recommendations for line drawings, grayscale drawings, halftones, and combination
figures. See below for sizing information.
Figure Alignment
Figures will be left-aligned on the page or column, so please design them accordingly.
Figure Width
Widths depend on article type layout and are listed in the tables below, but must be within the minimum of
3.27in/8.3cm wide and the maximum of 6.83in/17.35cm wide. Figures can have a maximum height of
9.19in/23.35 cm. If your figures have labels that are in 8 point type or if your figures are very detailed, it is
recommended that your figure be created so that it will span two columns. Images will be published in a
horizontal orientation, and cannot be rotated 90 degrees to have a vertical orientation. Please size your
figure widths to one of the column sizes listed below.
Article Type 
•2-column: Research Article, Expert Commentary, Guidelines and Guidance, Learning Forum, Neglected











•3-column: Editorial, Education, Essay, Health In Action, Historical and Philosophical Perspectives, Historical
Profiles and Perspectives, Interview, Message from ISCB, Opinion, Perspective, Policy Forum, Policy 
Platform, Research In Translation, Special Report, Viewpoint. 
Figure Types 
Line Art 
Line art has sharp, clean lines and geometrical shapes against a white background. Line art is typically used 
for tables, charts, graphs, and gene sequences. You can use a program like Illustrator to create high-quality 
line art. A minimum resolution of 300 ppi will maintain the crisp edges of the lines and shapes. 
•Format: TIFF or EPS
•Minimum Resolution: 300 ppi
Grayscale 
Grayscale figures contain varying tones of black and white. They contain no color, so grayscale is
synonymous with "black and white." The gray scale is divided into 256 sections with black at 0 and white at 
255. Software for preparation of grayscale art includes Photoshop.
•Format: TIFF or EPS
•Minimum Resolution: 300 ppi
Halftones 
The best example of a halftone is a photograph, but halftones include any image that uses continuous
shading or blending of colors or grays, such as gels, stains, microarrays, brain scans, and molecular
structures. To prepare and manipulate halftone images, use Photoshop or a comparable photo-editing
program.
•Format: TIFF
•Minimum Resolution: 300 ppi
Combination Figures 
Combination figures contain two or more types of images, for example, a halftone figure containing text. 
You should embed the images, group the objects, or flatten the layers, and flatten transparencies before 
saving as TIFF at a minimum of 300 ppi. 
•Format: TIFF
•Minimum Resolution: 300 ppi
3. Specific Reporting Guidelines











Methods sections of papers on research using human subject or samples must include ethics statements 
that specify:  
•The name of the approving institutional review board or equivalent committee(s). If approval was not
obtained, the authors must provide a detailed statement explaining why it was not needed 
•Whether informed consent was written or oral. If informed consent was oral, it must be stated in the
manuscript: 
◦Why written consent could not be obtained
◦That the Institutional Review Board (IRB) approved use of oral consent
◦How oral consent was documented
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender,
sexual orientation, or other socially constructed groupings, authors should:
•Explicitly describe their methods of categorizing human populations
•Define categories in as much detail as the study protocol allows
•Justify their choices of definitions and categories, including for example whether any rules of human
categorization were required by their funding agency 
•Explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status,
nutrition, environmental exposures, or similar factors in their analysis
In addition, outmoded terms and potentially stigmatizing labels should be changed to more current,
acceptable terminology. Examples: "Caucasian" should be changed to "white" or "of [Western] European
descent" (as appropriate); "cancer victims" should be changed to "patients with cancer."
For papers that include identifying, or potentially identifying, information, authors must download the 
Consent Form for Publication in a PLOS Journal (PDF), which the individual, parent, or guardian must sign
once they have read the paper and been informed about the terms of PLOS open-access license. The signed
consent form should not be submitted with the manuscript, but authors should securely file it in the
individual's case notes and the methods section of the manuscript should explicitly state that consent
authorization for publication is on file, using wording like:
The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to 
publish these case details. 
For more information about PLOS ONE policies regarding human subject research, see the Publication 
Criteria and Editorial Policies.  
3.2 Observational and Field Studies 












•Permits and approvals obtained for the work, including the full name of the authority that approved the
study; if none were required, authors should explain why 
•Whether the land accessed is privately owned or protected
•Whether any protected species were sampled
•Full details of animal husbandry, experimentation, and care/welfare, where relevant
